<DOC>
	<DOC>NCT02730169</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of BGS649 in male obese subjects with hypogonadotrophic hypogonadism. All subjects will be treated for a maximum of 24 weeks. Some subjects who complete 24 weeks of treatment will be invited to participate in a 6-month blinded safety extension study (Protocol MBGS206). The study is planned to enroll 268 subjects.</brief_summary>
	<brief_title>Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotrophic Hypogonadism</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<criteria>Adult male subject aged 18 to 65 years inclusive BMI &gt; 30 kg/m2 and &lt; 50 kg/m2 Serum total testosterone concentration below the normal range LH levels below the upper limit of normal Oestradiol levels within or above the normal range of approved assay At least two symptoms of androgen deficiency present for at least 2 months prior to the first Screening Visit, with at least one of these being a sexual dysfunction Evidence of clinically significant endocrinopathy at screening that may interfere with the study assessments Other types of hypogonadotrophic hypogonadism or primary hypogonadism Any other pituitary or hypothalamic disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hypogonadotropic</keyword>
	<keyword>hypogonadism</keyword>
	<keyword>testosterone</keyword>
</DOC>